Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.39 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL542283 | 0.87 | NOS2 (0.39) | DPP4DPP8DPP9NOS2NOS3 | |
| SCHEMBL30265157 | 0.85 | PRCP (0.44) | DPP4DPP8DPP9NOS2NOS3 | |
| SCHEMBL9362980 | 0.85 | PRCP (0.44) | DPP4DPP8DPP9NOS2NOS3 | |
| SCHEMBL995604 | 0.84 | NOS2 (0.46) | DPP4DPP8DPP9NOS2NOS3 | |
| SCHEMBL6859669 | 0.84 | NOS2 (0.46) | DPP4DPP8DPP9NOS2NOS3 | |
| SCHEMBL146828 | 0.84 | NOS2 (0.46) | DPP4DPP8DPP9NOS2NOS3 | |
| SCHEMBL302682 | 0.84 | NOS2 (0.41) | DPP4DPP8DPP9NOS2NOS3 | |
| SCHEMBL20839704 | 0.84 | PRCP (0.40) | DPP4DPP8DPP9NOS2NOS3 | |
| SCHEMBL20839978 | 0.84 | PRCP (0.40) | DPP4DPP8DPP9NOS2NOS3 | |
| SCHEMBL3662902 | 0.84 | NOS2 (0.37) | DPP4DPP8DPP9NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113695370-B | Natural eutectic ionic liquid and preparation method and application thereof | 河北科技大学 | 2022-06-07 | — | — | CN | disclosed |
| CN-113695370-A | Natural eutectic ionic liquid and preparation method and application thereof | 河北科技大学 | 2021-11-26 | — | — | CN | disclosed |
| US-7205384-B2 | Process for preparing peptidyl heterocyclic ketone derivatives | ORTHO-MCNEIL PHARMACEUTICAL INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20050059607-A1 | Process for preparing peptidyl heterocyclic ketone derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059607-A1 | Process for preparing peptidyl heterocyclic ketone derivatives | CMA1, TPSB2, TPSAB1 | DPP4 168/4885DPP8 222/4885DPP9 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.